All In Biotech

Drug Trial Radar · NCT04752696

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

41

Actual

Start

May 25, 2021

Primary completion

Dec 24, 2024

Study completion Dec 24, 2024

Sponsor

Lead sponsor
Cardiff OncologyIndustry
Sponsor type
Industry
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic PDAC.

Conditions

  • Pancreatic Ductal Adenocarcinoma

Interventions

  • OnvansertibDrug

    Oral capsule

  • Nanoliposomal irinotecanDrug

    Intravenous infusion

  • LeucovorinDrug

    Intravenous infusion

  • FluorouracilDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to approximately 91 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Phoenix

    Phoenix, Arizona

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • University of Kansas Medical Center

    Westwood, Kansas

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Inova Schar Cancer Institute

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.